Bispecifics & Multispecifics
VHH bi- and multi- specifics offer improved tumour targeting and tissue penetration. VHH can also be combined with conventional antibodies to create novel antibody formats and functionality.
Isogenica VHH antibodies are easily engineered with carefully designed affinities, valencies and specificities to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity.
Isogenica VHH Bi- and Multi-Specifics plug-and-play platform
Isogenica have developed fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific VHH and have exemplified this in in vitro studies.
Advantages of VHH in
VHH in Multispecifics
VHH as building blocks for immune and tumour cell-targeting
Watch our CSO deliver a webinar on the advantages of using VHH in multispecific formats to engage immune cells and target tumour cells.
Clinical landscape and applications of single domain VHH antibodies for optimisation of next generation T-cell immunodirection therapies
The whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities
Isogenica – University of Leicester
PHD student sponsorship
Through our collaboration with the University of Leicester and the sponsorship of a PhD student, we are able to demonstrate Isogenica’s VHH capabilities in multispecific formats.